Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992, pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor (EGFR) and Human EGF-like Receptor number 2 (HER2) immunohistochemical status with objective tumour responses
Neoplasms
DRUG: BIBW 2992
Maximum tolerated dose (MTD), up to 28 months|Incidence and intensity of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) associated with increasing doses of BIBW 2992, up to 28 months
Area under the plasma concentration-time curve (AUC) for different time points, up to 384 hours after first drug administration|Predose plasma concentration (Cpre) for different time points, Day 8 and 14|Minimum measured plasma concentration (Cmin) for different time points, up to 384 hours after first drug administration|Maximum measured plasma concentration (Cmax) for different time points, up to 384 hours after first drug administration|Time from dosing to the minimum plasma concentration (tmin) for different time points, up to 384 hours after first drug administration|Time from dosing to the maximum plasma concentration (tmax) for different time points, up to 384 hours after first drug administration|Terminal half-life (t1/2) for different time points, up to 384 hours after first drug administration|Mean residence time after oral administration (MRTpo) for different time points, up to 384 hours after first drug administration|Apparent clearance (CL/F) for different time points, up to 384 hours after first drug administration|Apparent volume of distribution during the terminal phase (Vz/F) for different time points, up to 384 hours after first drug administration|Accumulation ratio (RA), up to 384 hours after first drug administration|Modulation of biomarker (EGFR, p-EGFR, p-MAPK (mitogen-activated protein kinase), p-Akt, Ki-67, p-27KIP1) in skin biopsies prior to administration of BIBW 2992 and at the end of the first treatment period, Baseline and day 14|Modulation of biomarker (EGFR, p-EGFR, HER2, p-MAPK, p-Akt, Ki-67, p-27KIP1) in tumor biopsies prior to administration of BIBW 2992 and at the end of the first treatment period in 6 or more patients treated at the MTD, Baseline and day 14|Objective tumor responses, every 8 weeks up to 28 months|Correlation of EGFR, HER2, estrogen receptor and progesterone receptor immunohistochemical status as based on tumor biopsies or excisions obtained prior to this trial with objective tumor responses, up to 28 months
Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992, pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor (EGFR) and Human EGF-like Receptor number 2 (HER2) immunohistochemical status with objective tumour responses